Published in Psychopharmacology (Berl) on January 07, 2012
Application of cross-species PET imaging to assess neurotransmitter release in brain. Psychopharmacology (Berl) (2015) 0.79
Sensitivity of [(11)C]ORM-13070 to increased extracellular noradrenaline in the CNS - a PET study in human subjects. Psychopharmacology (Berl) (2015) 0.75
Adrenergic metabolic and hemodynamic effects of octopamine in the liver. Int J Mol Sci (2013) 0.75
Amphetamine decreases α2C-adrenoceptor binding of [11C]ORM-13070: a PET study in the primate brain. Int J Neuropsychopharmacol (2014) 0.75
Quantification of [(11)C]yohimbine binding to α2 adrenoceptors in rat brain in vivo. J Cereb Blood Flow Metab (2015) 0.75
Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse (2001) 4.03
Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab (2000) 2.95
Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety (2000) 2.76
Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J Neurosci (1998) 2.72
Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry (2001) 2.70
Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain (2004) 1.65
Increased dopamine tone during meditation-induced change of consciousness. Brain Res Cogn Brain Res (2002) 1.55
Amphetamine-induced displacement of [18F] fallypride in striatum and extrastriatal regions in humans. Neuropsychopharmacology (2006) 1.47
Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain. J Nucl Med (1993) 1.36
Kinetic modeling of [11C]raclopride: combined PET-microdialysis studies. J Cereb Blood Flow Metab (1997) 1.28
Effects of blood flow on [11C]raclopride binding in the brain: model simulations and kinetic analysis of PET data. J Cereb Blood Flow Metab (1994) 1.26
rTMS of the left dorsolateral prefrontal cortex modulates dopamine release in the ipsilateral anterior cingulate cortex and orbitofrontal cortex. PLoS One (2009) 1.22
Comparison of the alpha-adrenoceptor antagonist profiles of idazoxan (RX 781094), yohimbine, rauwolscine and corynanthine. Naunyn Schmiedebergs Arch Pharmacol (1984) 1.21
Dopamine release in ventral striatum during Iowa Gambling Task performance is associated with increased excitement levels in pathological gambling. Addiction (2010) 1.14
Isoflurane anesthesia enhances the inhibitory effects of cocaine and GBR12909 on dopamine transporter: PET studies in combination with microdialysis in the monkey brain. Brain Res (1999) 1.13
Methamphetamine potentiates ischemia/reperfusion insults after transient middle cerebral artery ligation. Stroke (2001) 1.12
Distribution and pharmacology of alpha 2-adrenoceptors in the central nervous system. J Physiol Pharmacol (1995) 1.07
Presynaptic alpha-2 adrenoceptors play a major role in the effects of idazoxan on cortical noradrenaline release (as measured by in vivo dialysis) in the rat. J Pharmacol Exp Ther (1987) 1.06
Actions of alpha2 adrenoceptor ligands at alpha2A and 5-HT1A receptors: the antagonist, atipamezole, and the agonist, dexmedetomidine, are highly selective for alpha2A adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol (1998) 1.03
PET measures of amphetamine-induced dopamine release in ventral versus dorsal striatum. Neuropsychopharmacology (1999) 1.02
Evaluation of [(11)C]MRB for assessment of occupancy of norepinephrine transporters: Studies with atomoxetine in non-human primates. Neuroimage (2010) 0.99
Methamphetamine causes sustained depression in cerebral blood flow. Brain Res (2010) 0.98
Specific in vivo binding to the norepinephrine transporter demonstrated with the PET radioligand, (S,S)-[11C]MeNER. Nucl Med Biol (2003) 0.97
Stimulation of the locus coeruleus elicits noradrenaline and dopamine release in the medial prefrontal and parietal cortex. J Neurochem (2005) 0.96
Elevated agonist binding to alpha2-adrenoceptors in the locus coeruleus in major depression. Biol Psychiatry (2003) 0.95
Detection of alpha2-adrenergic receptors in brain of living pig with 11C-yohimbine. J Nucl Med (2006) 0.93
Interplay among catecholamine systems: dopamine binds to alpha2-adrenergic receptors in birds and mammals. J Comp Neurol (2008) 0.92
Idazoxan (RX 781094) selectively antagonizes alpha 2-adrenoceptors on rat central neurons. Eur J Pharmacol (1984) 0.92
Cortical alpha-adrenoceptor downregulation by tricyclic antidepressants in the rat brain. Neurochem Int (2003) 0.91
Alpha2-adrenoceptor mediated co-release of dopamine and noradrenaline from noradrenergic neurons in the cerebral cortex. J Neurochem (2004) 0.91
Manipulation of norepinephrine metabolism with yohimbine in the treatment of autonomic failure. J Clin Pharmacol (1994) 0.90
Isoflurane anaesthesia differentially affects the amphetamine sensitivity of agonist and antagonist D2/D3 positron emission tomography radiotracers: implications for in vivo imaging of dopamine release. Mol Imaging Biol (2011) 0.89
Alpha2-adrenergic receptor blockade markedly potentiates duloxetine- and fluoxetine-induced increases in noradrenaline, dopamine, and serotonin levels in the frontal cortex of freely moving rats. J Neurochem (1997) 0.89
Sequential H(2)(15)O PET studies in baboons: before and after amphetamine. J Nucl Med (2002) 0.88
alpha2C adrenoceptors inhibit adenylyl cyclase in mouse striatum: potential activation by dopamine. J Pharmacol Exp Ther (1999) 0.87
In vivo measurement of density and affinity of the monoamine vesicular transporter in a unilateral 6-hydroxydopamine rat model of PD. J Cereb Blood Flow Metab (2007) 0.86
Regional cerebral blood flow response to oral amphetamine challenge in healthy volunteers. J Nucl Med (2001) 0.85
RX 821002 as a tool for physiological investigation of alpha(2)-adrenoceptors. CNS Drug Rev (2002) 0.84
Quantification and pharmacological characterization of dialysate levels of noradrenaline in the striatum of freely-moving rats: release from adrenergic terminals and modulation by alpha2-autoreceptors. J Neurosci Methods (2004) 0.83
Autoradiographic demonstration of increased alpha 2-adrenoceptor agonist binding sites in the hippocampus and frontal cortex of depressed suicide victims. J Neurochem (1994) 0.83
Comparison of changes in the extracellular concentration of noradrenaline in rat frontal cortex induced by sibutramine or d-amphetamine: modulation by alpha2-adrenoceptors. Br J Pharmacol (1999) 0.82
[3H]RS79948-197 binding to human, rat, guinea pig and pig alpha2A-, alpha2B- and alpha2C-adrenoceptors. Comparison with MK912, RX821002, rauwolscine and yohimbine. Eur J Pharmacol (1998) 0.81
PET study of the [11C]raclopride binding in the striatum of the awake cat: effects of anaesthetics and role of cerebral blood flow. Eur J Nucl Med Mol Imaging (2002) 0.81
Inhibition of [11C]mirtazapine binding by alpha2-adrenoceptor antagonists studied by positron emission tomography in living porcine brain. Synapse (2006) 0.80
Circulating norepinephrine and cerebrovascular control in conscious humans. Clin Physiol Funct Imaging (2003) 0.79
Mapping the amphetamine-evoked dopamine release in the brain of the Göttingen minipig. Brain Res Bull (2005) 0.78
The d-amphetamine-treated Göttingen miniature pig: an animal model for assessing behavioral effects of antipsychotics. Psychopharmacology (Berl) (2009) 0.78
Effects of amphetamine and evoked dopamine release on [11C]raclopride binding in anesthetized cats. Neuropsychopharmacology (2002) 0.78
Identification of drugs subtype-selective for alpha 2A-, alpha 2B-, and alpha 2C-adrenoceptors in the pig cerebellum and kidney cortex. Eur J Pharmacol (1995) 0.78
Assessment of dynamic susceptibility contrast cerebral blood flow response to amphetamine challenge: a human pharmacological magnetic resonance imaging study at 1.5 and 4 T. Magn Reson Med (2006) 0.78
Reproducibility of the distribution of carbon-11-SCH 23390, a dopamine D1 receptor tracer, in normal subjects. J Nucl Med (1998) 0.77
Estimation of endogenous noradrenaline release in rat brain in vivo using [3H]RX 821002. Synapse (2005) 0.77
Changes in cerebral blood flow and mental state after amphetamine challenge in schizophrenic patients. Neuropsychobiology (1989) 0.76
Regional cerebral blood flow in cocaine- versus methamphetamine-dependent patients with a history of alcoholism. Int J Neuropsychopharmacol (2001) 0.76
Autoradiographic studies of central alpha 2A- and alpha 2C-adrenoceptors in the rat using [3H]MK912 and subtype-selective drugs. Brain Res (1997) 0.75
Distribution of catecholamines in the central nervous system of the pig. Brain Res Bull (1993) 0.75
Effect of chronic administration of antidepressants on alpha 2-adrenoceptors in the locus coeruleus and its projection fields in rat brain determined by quantitative autoradiography. Neuropsychopharmacology (1993) 0.75
Regional distribution of catecholamines in monkey cerebral cortex, evidence for a dopaminergic innervation of the primate prefrontal cortex. Neurosci Lett (1978) 0.75
Positron emission tomography (PET) imaging with [11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts. Cancer Res (2009) 1.39
FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial. Radiother Oncol (2012) 1.24
Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation. Diabetes (2008) 1.15
Quantitative micro positron emission tomography (PET) imaging for the in vivo determination of pancreatic islet graft survival. Nat Med (2006) 1.10
Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice. Diabetes (2008) 1.10
Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage. Eur J Nucl Med Mol Imaging (2008) 1.07
Brain incorporation of [11C]arachidonic acid in young healthy humans measured with positron emission tomography. J Cereb Blood Flow Metab (2002) 1.07
Intracerebroventricular corticotropin-releasing factor increases limbic glucose metabolism and has social context-dependent behavioral effects in nonhuman primates. Proc Natl Acad Sci U S A (2002) 1.03
Imaging of enzyme replacement therapy using PET. Proc Natl Acad Sci U S A (2010) 1.03
Increase in dopamine turnover occurs early in Parkinson's disease: evidence from a new modeling approach to PET 18 F-fluorodopa data. J Cereb Blood Flow Metab (2002) 1.01
Radiosynthesis and in vivo evaluation of [(11)C]MP-10 as a positron emission tomography radioligand for phosphodiesterase 10A. Nucl Med Biol (2011) 1.00
Abnormal metabolic brain networks in a nonhuman primate model of parkinsonism. J Cereb Blood Flow Metab (2011) 0.99
Electroconvulsive therapy alters dopamine signaling in the striatum of non-human primates. Neuropsychopharmacology (2010) 0.95
Can hypoxia-PET map hypoxic cell density heterogeneity accurately in an animal tumor model at a clinically obtainable image contrast? Radiother Oncol (2009) 0.94
Parametric and regional maps of free serotonin 5HT1A receptor sites in human brain as function of age in healthy humans. Neuropsychopharmacology (2007) 0.92
Human retinal pigment epithelial cell implants ameliorate motor deficits in two rat models of Parkinson disease. J Neuropathol Exp Neurol (2007) 0.92
In vivo receptor assay with multiple ligand concentrations: an equilibrium approach. J Cereb Blood Flow Metab (2002) 0.91
Assessing hypoxia in animal tumor models based on pharmocokinetic analysis of dynamic FAZA PET. Acta Oncol (2010) 0.90
Imaging hypoxia in xenografted and murine tumors with 18F-fluoroazomycin arabinoside: a comparative study involving microPET, autoradiography, PO2-polarography, and fluorescence microscopy. Int J Radiat Oncol Biol Phys (2008) 0.90
Characterization and survival of long-term implants of human retinal pigment epithelial cells attached to gelatin microcarriers in a model of Parkinson disease. J Neuropathol Exp Neurol (2007) 0.88
In vivo measurement of density and affinity of the monoamine vesicular transporter in a unilateral 6-hydroxydopamine rat model of PD. J Cereb Blood Flow Metab (2007) 0.86
Electroconvulsive shock enhances striatal dopamine D1 and D3 receptor binding and improves motor performance in 6-OHDA-lesioned rats. J Psychiatry Neurosci (2007) 0.86
Inhibition of tumor lactate oxidation: consequences for the tumor microenvironment. Radiother Oncol (2011) 0.85
Serotonergic modulation of receptor occupancy in rats treated with L-DOPA after unilateral 6-OHDA lesioning. J Neurochem (2012) 0.85
Electroconvulsive shock decreases binding to 5-HT2 receptors in nonhuman primates: an in vivo positron emission tomography study with [18F]setoperone. Biol Psychiatry (2005) 0.85
A PET study of effects of chronic 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") on serotonin markers in Göttingen minipig brain. Synapse (2007) 0.85
Accessing radiation response using hypoxia PET imaging and oxygen sensitive electrodes: a preclinical study. Radiother Oncol (2011) 0.85
Evaluation of the integrity of the dopamine system in a rodent model of Parkinson's disease: small animal positron emission tomography compared to behavioral assessment and autoradiography. Mol Imaging Biol (2006) 0.85
Levodopa and pramipexole effects on presynaptic dopamine PET markers and estimated dopamine release. Eur J Nucl Med Mol Imaging (2010) 0.85
[N-methyl-11C]cholylsarcosine, a novel bile acid tracer for PET/CT of hepatic excretory function: radiosynthesis and proof-of-concept studies in pigs. J Nucl Med (2012) 0.85
Molecular tools for assessing human depression by positron emission tomography. Eur Neuropsychopharmacol (2009) 0.84
Radiosynthesis and characterization of 11C-GSK215083 as a PET radioligand for the 5-HT6 receptor. J Nucl Med (2012) 0.83
Time profile of cerebral [18F]6-fluoro-L-DOPA metabolites in nonhuman primate: implications for the kinetics of therapeutic L-DOPA. Front Biosci (2004) 0.82
Animal models of neurodegenerative disease: insights from in vivo imaging studies. Mol Imaging Biol (2007) 0.81
Positron emission tomography receptor assay with multiple ligand concentrations: an equilibrium approach. Methods Enzymol (2004) 0.81
Phosphodiesterase 10A PET radioligand development program: from pig to human. J Nucl Med (2014) 0.81
Quantitative in vitro phosphor imaging using [3H] and [18F] radioligands: the effects of chronic desipramine treatment on serotonin 5-HT2 receptors. J Neurosci Methods (2005) 0.80
[11C]Mirtazapine binding in depressed antidepressant nonresponders studied by PET neuroimaging. Psychopharmacology (Berl) (2009) 0.80
Inhibition of [11C]mirtazapine binding by alpha2-adrenoceptor antagonists studied by positron emission tomography in living porcine brain. Synapse (2006) 0.80
Gradients of dopamine D1- and D2/3-binding sites in the basal ganglia of pig and monkey measured by PET. Neuroimage (2004) 0.79
The influence of measurement uncertainties on the evaluation of the distribution volume ratio and binding potential in rat studies on a microPET R4: a phantom study. Phys Med Biol (2005) 0.79
In vivo identification and specificity assessment of mRNA markers of hypoxia in human and mouse tumors. BMC Cancer (2011) 0.79
PET imaging of tumor hypoxia using 18F-labeled pimonidazole. Acta Oncol (2013) 0.79
Dopamine D3 receptor antagonists: the quest for a potentially selective PET ligand. Part 3: Radiosynthesis and in vivo studies. Bioorg Med Chem Lett (2009) 0.79
Behaviour of [11C]R(-)- and [11C]S(+)-rolipram in vitro and in vivo, and their use as PET radiotracers for the quantificative assay of PDE4. Synapse (2005) 0.78
Behavioral response to novelty correlates with dopamine receptor availability in striatum of Göttingen minipigs. Behav Brain Res (2005) 0.78
Stereoselective neuroimaging in vivo. Eur Neuropsychopharmacol (2007) 0.78
Receptor occupancy of mirtazapine determined by PET in healthy volunteers. Psychopharmacology (Berl) (2007) 0.78
Direct intranigral administration of an ubiquitin proteasome system inhibitor in rat: behavior, positron emission tomography, immunohistochemistry. Exp Neurol (2013) 0.78
[11C]-NS 4194 versus [11C]-DASB for PET imaging of serotonin transporters in living porcine brain. Synapse (2003) 0.78
Pathological gambling: relation of skin conductance response to dopaminergic neurotransmission and sensation-seeking. Eur Neuropsychopharmacol (2010) 0.78
Mapping the amphetamine-evoked dopamine release in the brain of the Göttingen minipig. Brain Res Bull (2005) 0.78
Biodistribution and radiation dosimetry of [N-methyl-11C]mirtazapine, an antidepressant affecting adrenoceptors. Appl Radiat Isot (2003) 0.78
Neuroimaging of mirtazapine enantiomers in humans. Psychopharmacology (Berl) (2008) 0.77
PET neuroimaging of [11C]mirtazapine enantiomers in pigs. Eur Neuropsychopharmacol (2005) 0.77
How Relevant Are Imaging Findings in Animal Models of Movement Disorders to Human Disease? Curr Neurol Neurosci Rep (2015) 0.77
Rett syndrome: investigation of nine patients, including PET scan. Can J Neurol Sci (2002) 0.76
Molecular Neurobiology of Depression: PET Findings on the Elusive Correlation with Symptom Severity. Front Psychiatry (2013) 0.76
Effects of anesthesia and species on the uptake or binding of radioligands in vivo in the Göttingen minipig. Biomed Res Int (2013) 0.75
[N-methyl-11C]Mirtazapine for positron emission tomography neuroimaging of antidepressant actions in humans. Psychopharmacology (Berl) (2004) 0.75
Imaging imidazoline-I2 binding sites in porcine brain using 11C-BU99008. J Nucl Med (2012) 0.75
Antiparkinsonian mechanism of electroconvulsive therapy in MPTP-lesioned non-human primates. Neurodegener Dis (2012) 0.75
Functional neuroimaging in Parkinson's disease. Expert Opin Med Diagn (2011) 0.75